-
Symeres CEO Eelco Ebbers Speaks on “Leaders in Life Sciences” Podcast
Symeres CEO Eelco Ebbers recently shared his insights on the renowned “Leaders in Life Sciences” podcast, hosted by Henk Jan Out. Recorded at the Pivot Park in Oss, near our subsidiary Oncolines, the interview delved into various facets of Eelco’s journey, including his educational background in organic chemistry, Symeres’ services and strategy, as well as personal interests such as family and hobbies.
-
Organix: New facility
On March 26th we had the Grand Opening of our brand new, state-of-the-art Organix synthetic and analytical chemistry laboratories in Woburn, just outside Boston MA.
-
Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ-1 Subunit of Voltage-Gated Calcium Channel and the μ-Opioid Receptor
In collaboration with WeLab Barcelona, we report the synthesis and biological activity of novel pain therapeutics, which target both Cavα2δ-1 and MOR. One of these disubstituted pyrrolidines demonstrated an analgesic effect in various rodent models of pain, and a lack of unfavorable off-target interactions, showing no evident signs of withdrawal or tolerance. Click on the link below for a short summary of this publication.
-
Innovative macrocycles as powerful Mcl-1 inhibitors
This is a recap of the article “Development of potent Mcl-1 inhibitors: structural investigations on macrocycles originating from a DNA-encoded chemical library screen” published in the Journal of Medicinal Chemistry. Myeloid cell leukemia 1 (Mcl-1) is a protein that plays a crucial role in the regulation of cell survival and cell death. It is part of a family of proteins called the Bcl-2 family, which are known for their involvement in controlling the life span of cells.
-
Oncolines unveils new State-of-the-Art Laboratories
In a significant stride towards advancing cancer research and drug development, Oncolines, has officially received the keys to its new laboratories and offices situated within the prestigious Curie Building on the Pivot Park in Oss, the Netherlands.
-
Our Article Published in the Journal of Medicinal Chemistry
Symeres is thrilled to announce the publication of a scientific article in the prestigious Journal of Medicinal Chemistry with our colleague Koen Hekking as the main author and many more Symerians involved! We are incredibly proud of our colleagues who were instrumental in the research and development of this innovative project.
-
Peter Molenveld Assumes Role as Secretary of KNCV (Royal Netherlands Chemical Society)
Symeres is proud to announce that our colleague Dr. Peter Molenveld has been appointed as a board member of the Royal Netherlands Chemical Society (KNCV). His appointment as Secretary marks a crucial milestone in Molenveld’s career and signifies his commitment to advancing the interests of the chemical community in the Netherlands.
-
Luc van Hijfte Assumes Presidency of EFMC, Spearheading Advances in Medicinal Chemistry and Chemical Biology
Symeres is thrilled to announce that as of January 1, 2024, our sr. Vice President Dr. Luc van Hijfte has taken the helm as the President of the European Federation of Medicinal Chemistry and Chemical Biology (EFMC).
-
Interview with the Computer-Aided Drug Design (CADD) Department
Our Computer Aided Drug Design department supports our clients’ drug discovery projects with some of the best (predictive) software.
-
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.” Dooyoung Jung, CEO of Pinotbio.
An in-depth interview with Doo Young Jung, the founder and CEO of our client Pinotbio in South Korea, focused on the challenge of cancer resistance/relapse
-
New scientific services from Symeres
We’re proud to announce that our brand new CMC facility at the Exemplify site of Symeres in New Jersey has been successfully completed. GMP drug product R&D facilities that will allow it to provide end-to-end services ranging from GMP and non-GMP drug product development to phase 1 and 2 clinical supplies of various oral, parenteral, and topical formulation dosage forms.
-
Interview with the new Managing Director of Symeres Groningen
On October 2, Dr Melloney Dröge started in her new role as Managing Director for the Groningen site.
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
